Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% EV-to-FCF is 39.14 as of Aug. 03, 2026. The stock has 1 warning sign investors should review. Among 100 Medical Diagnostics & Research companies, Invitro International ranks worse than 68% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Invitro International's Enterprise Value is $0.55 Mil.
Invitro International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01 Mil. Therefore, Invitro International's EV-to-FCF for today is 39.14.
The historical rank and industry rank for Invitro International's EV-to-FCF or its related term are showing as below:
IVRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -418.02 Med: -59.23 Max: 401.33
Current: 39.14
During the past 9 years, the highest EV-to-FCF of Invitro International was 401.33. The lowest was -418.02. And the median was -59.23.
IVRO's EV-to-FCF is ranked worse than 68% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.65
vs IVRO: 39.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invitro International (OTCPK:IVRO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invitro International's PE Ratio (TTM) for today is calculated as:
Invitro International's share price for today is $0.0679.
Invitro International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Invitro International's EV-to-FCF falls into.
Invitro International's current Enterprise Value is $0.55 Mil.
Invitro International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a EV-to-FCF of 39.14 as of Aug. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #68 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 68%.
Is Invitro International's EV-to-FCF too high?
Invitro International's current EV-to-FCF is 39.14. The Medical Diagnostics & Research industry median EV-to-FCF is 25.65. Invitro International's value of 39.14 is 52.6% above this industry median. Based on the distribution chart, Invitro International ranks #68 out of 100 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Invitro International's EV-to-FCF compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #68 out of 100 companies for EV-to-FCF. This places Invitro International in the lower half of its industry. The industry median EV-to-FCF is 25.65. Invitro International's value of 39.14 is 52.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.65, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current EV-to-FCF of 39.14 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current EV-to-FCF is 39.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current EV-to-FCF is 39.14 and 52.6% above the Medical Diagnostics & Research industry median of 25.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Invitro International (IVRO), the current EV-to-FCF is 39.14 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
